What is the recommended evaluation and hormone replacement therapy regimen for a perimenopausal woman presenting with irregular bleeding?

Treatment of Irregular Perimenopausal Bleeding with HRT

Before initiating any hormone therapy, you must first exclude endometrial pathology through transvaginal ultrasound and endometrial biopsy in women ≥45 years with irregular bleeding.

---

Mandatory Pre-Treatment Evaluation

All perimenopausal women presenting with irregular bleeding require structural and histologic assessment before hormone therapy is prescribed. 1

Step 1: Imaging Assessment

• Order transvaginal ultrasound combined with transabdominal imaging to measure endometrial thickness, identify polyps, fibroids, adenomyosis, or malignancy 1
• TVUS distinguishes structural causes (polyps, leiomyomas, hyperplasia, cancer) from non-structural etiologies (ovulatory dysfunction) 1
• If focal lesions are suspected or visualization is inadequate, proceed to saline-infusion sonohysterography (96–100% sensitivity for endometrial pathology) 1

Step 2: Endometrial Sampling

• Perform endometrial biopsy in all women ≥45 years with abnormal bleeding, regardless of ultrasound findings 1
• Biopsy is also mandatory when endometrial thickness ≥10 mm or risk factors are present (obesity, diabetes, hypertension, nulliparity, PCOS) 1
• Office Pipelle biopsy achieves 99.6% sensitivity for detecting carcinoma 1
• If initial biopsy is inadequate or bleeding persists despite benign results, escalate to hysteroscopy with directed biopsy—blind sampling has a 10% false-negative rate 1

Step 3: Laboratory Evaluation

• Measure TSH and prolactin to identify reversible endocrine causes of ovulatory dysfunction 1, 2
• Exclude pregnancy with β-hCG if clinically indicated 2

---

First-Line Hormone Therapy After Pathology Is Excluded

Combined Hormonal Contraceptives (Preferred for Most)

Combined oral contraceptives or the contraceptive ring are first-line medical therapy for perimenopausal irregular bleeding caused by ovulatory dysfunction. 1

• Use low-dose formulations containing 30–35 μg ethinyl estradiol plus levonorgestrel or norgestimate 2
• CHCs provide cycle regulation, contraception, and endometrial protection through progestational opposition to unopposed estrogen 3
• Contraindications to estrogen-containing products include personal history of thromboembolism, stroke, migraine with aura, uncontrolled hypertension, or breast cancer 1

Cyclic Progestin Therapy (When Estrogen Is Contraindicated)

For women who cannot use estrogen, prescribe cyclic progestin therapy such as medroxyprogesterone acetate 10 mg daily for 10–14 days each month 1, 3

• Progestogens cancel the proliferative and mitogenic effect of estrogens, even when administered sequentially 3
• This regimen provides endometrial protection and reduces bleeding while avoiding estrogen exposure 3

Levonorgestrel Intrauterine System (Most Effective Option)

The levonorgestrel-releasing IUD is the most effective medical therapy for perimenopausal menorrhagia 4

• Superior to oral progestogens, combined oral contraceptives, tranexamic acid, and NSAIDs in reducing menstrual blood loss 4
• Provides local endometrial suppression with minimal systemic progestogen exposure 4

---

Alternative Medical Options

Non-Hormonal Agents

• Tranexamic acid reduces menstrual blood loss through antifibrinolytic action 4
• NSAIDs (mefenamic acid 500 mg three times daily or celecoxib 200 mg daily for 5–7 days during bleeding) reduce prostaglandin-mediated blood loss 2, 4
• These agents are less effective than hormonal therapies but useful when hormones are contraindicated 4

---

When to Escalate to Surgical Management

If bleeding persists despite appropriate medical therapy, is unacceptable to the patient, or medical therapy is contraindicated or not tolerated, offer surgical options. 1

• Endometrial ablation (second-generation techniques: thermal balloon, microwave, radiofrequency) is appropriate for women who have completed childbearing 1
• Hysterectomy is definitive treatment when medical and ablative therapies fail 1

---

Critical Pitfalls to Avoid

Never Start Hormone Therapy Without Tissue Diagnosis

• Initiating HRT in a perimenopausal woman with irregular bleeding before excluding malignancy exposes the patient to delayed cancer diagnosis 1
• Anovulatory cycles in perimenopause create unopposed estrogen exposure, markedly raising the risk of endometrial hyperplasia and carcinoma 1
• Ultrasound alone cannot differentiate hyperplasia, polyps, or malignancy—histologic sampling is mandatory 1

Do Not Accept Inadequate Biopsy Results as Reassuring

• Office endometrial biopsy has a 10% false-negative rate 1
• Persistent bleeding after a benign or non-diagnostic biopsy mandates hysteroscopy with directed sampling 1

Recognize That Standard HRT Is Not Appropriate for Perimenopausal Bleeding Control

• The evidence for long-term hormone therapy (conjugated equine estrogen ± medroxyprogesterone acetate) addresses cardiovascular and fracture outcomes in postmenopausal women, not cycle regulation in perimenopause 5
• Combined continuous HRT may increase stroke (RR 1.39), venous thromboembolism (RR 2.03), and breast cancer (RR 1.27) risk 5
• For perimenopausal bleeding control, use contraceptive-dose hormones (CHCs or cyclic progestins), not postmenopausal HRT formulations 1, 3

---

Evidence Quality and Applicability

The recommendation for mandatory endometrial sampling in women ≥45 years with abnormal bleeding is supported by high-quality guideline evidence from ACOG, NCCN, and ESMO 1. The diagnostic accuracy of Pipelle biopsy (99.6% sensitivity) is derived from large cohort studies (Level I evidence) 1. Medical management recommendations are based on systematic reviews and randomized controlled trials 4, 5, though most long-term HRT data come from postmenopausal populations and may not fully represent perimenopausal physiology 5.